Clinical trial analysis in this limited patient population found no clinically meaningful difference in risankizumab exposure between patients 65 years of age or older and adult population.
Insufficient data to make a recommendation regarding safety in pregnancy.
As it is a monoclonal antibody, its safety profile is expected to be similar to that of other biologics, and it can be continued throughout pregnancy.12
Insufficient data regarding the safety in breastfeeding.